| Added by | standudu |
|---|---|
| Group name | EquipeCTCS |
| Item Type | Note |
| Note | The following values have no corresponding Zotero field: auth-address: Department of Medical Oncology, Institut Bergonie Comprehensive Cancer Centre, Universite de Bordeaux, INSERM U916, Bordeaux h.bonnefoi@bordeaux.unicancer.fr. Department of Medical Oncology, Centre Val D'Aurelle-Paul Lamarque, Montpellier. Department of Medical Oncology, Gustave Roussy, Villejuif. Department of Medical Oncology, Centre Henri Becquerel, Rouen. Department of Medical Oncology, Centre Hospitalier Universitaire, Limoges, France. Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. Department of Medical Oncology, Institute of Oncology, Ljubljana, Ljubljana University Clinic, Golnik, Slovenia. Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France. Gyneco-Oncology Unit, Hopitaux Universitaires de Geneve (HUG), Geneva, Switzerland. Department of Medical Oncology, Institut Bergonie Comprehensive Cancer Centre, Universite de Bordeaux, INSERM U916, Bordeaux. Department of Medical Oncology, Hopital St Elisabeth, Namur. Department of Medical Oncology, Centre Hospitalier Universitaire (Sart Tilman), Liege, Belgium. Medical Oncology and Clinical Research Unit, Ensemble Hospitalier de L'Institut Curie, Hopital Rene Huguenin, St-Cloud. Department of Medical Oncology, Centre Leon Berard, Lyon, France. Department of Statistics, European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium. Edinburgh Breast Unit and Edinburgh University Cancer Research Centre, Western General Hospital, Edinburgh, UK. alt-title: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO number: 2 accession-num: 25467016 |
| Tags | _EndnoteXML import |
| Date Added | 2018/11/14 - 15:25:02 |
| Date Modified | 2018/11/14 - 15:25:02 |
| Parent item | Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study |
Institut de Recherche en Cancérologie de
